Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Dyax Loses Genzyme As DX-88 Partner, But Still Eyes 2008 Approval

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm is yet to make a decision on whether it will find new partner or continue development on its own.

You may also be interested in...



Three Firms Aim To Launch Therapies For Hereditary Angioedema In 2008

Lev, which submitted a BLA in July, is vying with Dyax and German firm Jerini to launch drugs next year.

Three Firms Aim To Launch Therapies For Hereditary Angioedema In 2008

Lev, which submitted a BLA in July, is vying with Dyax and German firm Jerini to launch drugs next year.

Dyax Launches Confirmatory DX-88 Study Requested By FDA

Late 2008 approval for the experimental hereditary angioedema treatment is anticipated.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS065661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By